Taysha Gene Therapies, Inc.
TSHA · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $9.77M | $8.33M | +17.3% |
| Operating income | −$110M | −$91.5M | −20.8% |
| Net income | −$109M | −$89.3M | −22.1% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 12, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $0K | $0K | |
| Operating income | −$41.9M | −$34.0M | −23.2% |
| Net income | −$39.1M | −$32.7M | −19.6% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Taysha Gene Therapies's revenue in FY2025?
- $9.77M in FY2025 (Fiscal year ended Dec 31, 2025), +17.3% vs $8.33M a year earlier, per its 10-K filed Mar 2026.
- Was Taysha Gene Therapies profitable in FY2025?
- No: net income was −$109M and operating income −$110M in FY2025.
- What was Taysha Gene Therapies's revenue in Q3 2026?
- $0K (n/a vs a year earlier), per its Form 10-Q filed Nov 12, 2026.